308 related articles for article (PubMed ID: 26432092)
1. Novel Therapies in IBS-D Treatment.
Nee J; Zakari M; Lembo AJ
Curr Treat Options Gastroenterol; 2015 Dec; 13(4):432-40. PubMed ID: 26432092
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
3. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
4. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.
Nee J; Zakari M; Lembo AJ
Expert Opin Pharmacother; 2015; 16(18):2781-92. PubMed ID: 26558923
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.
Lacy BE
Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872
[TBL] [Abstract][Full Text] [Related]
7. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions.
Cangemi DJ; Lacy BE
Therap Adv Gastroenterol; 2019; 12():1756284819878950. PubMed ID: 31632456
[TBL] [Abstract][Full Text] [Related]
8. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
9. Current gut-directed therapies for irritable bowel syndrome.
Chang HY; Kelly EC; Lembo AJ
Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950
[TBL] [Abstract][Full Text] [Related]
10. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE
Int J Gen Med; 2016; 9():7-17. PubMed ID: 26929659
[TBL] [Abstract][Full Text] [Related]
13. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
Brenner DM; Dove LS; Andrae DA; Covington PS; Gutman C; Chey WD
Neurogastroenterol Motil; 2018 Mar; ():e13331. PubMed ID: 29575372
[TBL] [Abstract][Full Text] [Related]
14. Journal of Clinical Gastroenterology Lectureship Dubai 2022 : Management of Irritable Bowel Syndrome With Diarrhea.
Marasco G; Cremon C; Barbaro MR; Stanghellini V; Barbara G
J Clin Gastroenterol; 2024 Mar; 58(3):221-231. PubMed ID: 38227850
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.
Fragkos KC
Clin Exp Gastroenterol; 2017; 10():229-240. PubMed ID: 28989282
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
17. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.
Levio S; Cash BD
Therap Adv Gastroenterol; 2017 Sep; 10(9):715-725. PubMed ID: 28932272
[TBL] [Abstract][Full Text] [Related]
18. Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.
Chang C
Clin Exp Gastroenterol; 2018; 11():335-345. PubMed ID: 30288076
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
Corsetti M; Whorwell P
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):285-292. PubMed ID: 28276811
[TBL] [Abstract][Full Text] [Related]
20. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.
Barshop K; Staller K
Ther Adv Chronic Dis; 2017 Nov; 8(11):153-160. PubMed ID: 29090081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
